|
NP
CHRONICLES Clinical Awareness Brief |
Peptides
Are Having a Moment — Here's What NPs Need to Know Right Now
An FDA advisory panel is reconsidering compounding rules for
BPC-157 and six other peptides, even as the basic science press stays deeply
skeptical of the mail-order peptide trade.
If
your patients haven't asked you about peptides yet, they probably will soon.
This week the FDA convened a two-day advisory panel to reconsider whether
compounding pharmacies should be allowed to prepare seven specific peptides —
including BPC-157, a favorite of biohacking and "research use only"
marketplaces — under prescription and physician oversight. The timing lands
right on top of two other useful reads: a widely circulated science-blog
takedown of the mail-order peptide trade, and a comprehensive academic review
of legitimate, FDA-approved peptide therapeutics. Read together, the three
pieces sketch out exactly where the clinical conversation with patients needs
to go.
Two Very Different Worlds Called
"Peptides"
Part
of what makes this topic slippery in the exam room is that "peptide"
means two different things depending on who is saying it. Chemically, a peptide
is simply a short chain of amino acids — a category broad enough to include
everything from digestive breakdown products to insulin itself. Clinically and
commercially, "Peptides" (capital P, as science writer Derek Lowe
puts it) has become shorthand for a specific class of injectable, mail-order
compounds marketed for muscle building, fat loss, hair regrowth, tissue repair,
and anti-aging — most of them sold with little to no human trial data behind
them.
There
are more than 80 FDA-approved peptide drugs on the market today, spanning
diabetes care (the GLP-1 receptor agonists), oncology, cardiovascular disease,
and antimicrobial therapy. Those drugs went through the same
design-synthesis-modification-trial pipeline as any other pharmaceutical. The
peptides driving patient questions in your clinic right now — BPC-157, various
growth-hormone-releasing peptides, and others sold through gray-market
suppliers — have not.
What's Actually on the Table at the FDA
This Week
The
panel isn't deciding whether to approve BPC-157 or its peers as drugs. It's
deciding whether compounding pharmacies can legally prepare them under a
prescription, for a specific diagnosis, with physician oversight — a narrower
and more clinically supervised pathway than the current gray market, but still
well short of full FDA approval with its accompanying efficacy and
manufacturing standards.
●
BPC-157 is marketed for
tissue and injury healing. As one physician noted in a recent STAT piece, it
has been studied in roughly a dozen human subjects — compare that to the
six-figure trial populations behind statins or GLP-1 drugs.
●
The Biden-era FDA had
already added nearly 20 peptides to the list of substances compounding
pharmacies should not prepare, citing insufficient safety data.
●
Most of the current
advisory panel and agency staff involved in that 2020s-era decision are no
longer in their roles, and HHS Secretary Robert F. Kennedy Jr. has publicly
described himself as a supporter of these unapproved therapies.
●
The outcome will not
constitute FDA approval of any of these peptides as drugs — it would only
change who is legally allowed to compound them and under what supervision.
Why the Science Press Is Sounding the Alarm
Lowe's
post (published on his long-running chemistry blog) walks through the
mechanistic case for caution, and it's worth internalizing the framework even
if you never mention his name to a patient:
●
Bioactivity is not the
same as a known safety profile. Short peptides can have dramatic biological
effects, but the field is still discovering off-target activity even for
extremely well-studied hormones like insulin.
●
Reactivating growth
pathways carries a generic cancer-risk concern. Growth hormone axis peptides in
particular risk recreating the physiology of acromegaly — bone overgrowth,
joint pain, hypertension, and type 2 diabetes — when taken outside physiologic feedback
control.
●
Sourcing is a black box.
Patients ordering from unregulated suppliers have no way to verify purity,
concentration, or degradation, and no regulatory body compelling the supplier
to care.
●
The appeal is often
ideological as much as clinical — a "do my own research,"
anti-regulatory framing that can lead patients to discontinue well-evidenced
therapies (statins, in the STAT anecdote) in favor of a compound studied in a
literal handful of people.
|
AMBER FLAG — Don't Let the GLP-1 Comparison Do the
Wrong Work Patients will sometimes reason,
"GLP-1 drugs are peptides too, and those turned out great — so why not
this one?" It's worth naming that logical leap directly. Semaglutide and
liraglutide reached the market only after extensive sequence modification,
half-life extension, and trial programs involving well over 100,000 patients
combined. A gray-market peptide with a study population in the dozens has
none of that behind it. Same molecular category, entirely different evidence
base. |
Case From Practice
|
"My Trainer Said BPC-157 Would Heal My Rotator
Cuff Faster" A 34-year-old patient with a partial
supraspinatus tear, already referred to physical therapy, asks whether you
can prescribe or approve a BPC-157 regimen he found through an online fitness
coach. He has done "his own research" and read that it's
"basically a natural healing peptide." This is a good opening for
motivational, non-adversarial patient education rather than a flat
refusal-and-move-on. Points worth hitting: ●
Validate the goal (faster, better healing) before addressing the
method — the desire to heal well is reasonable even if the chosen tool isn't. ●
Name the evidence gap plainly: BPC-157 has essentially no
controlled human trial data for musculoskeletal healing, and no established
dosing, purity standard, or long-term safety profile. ●
Ask where he'd be sourcing it — most patients haven't considered
that an unregulated supplier has no incentive to guarantee what's actually in
the vial. ●
Redirect to what does have evidence for tendon/rotator cuff
recovery: structured PT progression, load management, and, where appropriate,
evidence-based adjuncts you can actually document and monitor. ●
Document the conversation. If the patient proceeds through a
gray-market source anyway, you want a clear record that risks were discussed. |
Clinical Bottom Line
|
●
Legitimate, FDA-approved peptide drugs (GLP-1 receptor agonists,
insulin analogues, GnRH-derived agents, ziconotide, etc.) are a mature,
well-evidenced drug class — don't let "peptide" become a red-flag
word in your own head. ●
Gray-market "research peptides" like BPC-157 are a
separate category with minimal human data, unverified sourcing, and real
theoretical risk (growth-pathway activation, cancer risk, contamination). ●
The FDA's current review is about compounding access under
prescription, not drug approval — expect this to change the conversation with
patients even if it doesn't change the evidence base. ●
Anticipate the question before the patient asks it. A brief,
non-judgmental script ("tell me what you've read, here's what we
actually know") keeps patients from sourcing these compounds entirely
outside medical supervision. |
Board Prep: Know Your Peptide Drug Classes
Certification
exams love peptide pharmacology because it cuts across endocrine,
cardiovascular, GI, and oncology content. A few high-yield associations worth
drilling:
●
GLP-1 receptor agonists
(exenatide, liraglutide, semaglutide, dulaglutide) — T2DM and weight
management; GI side effects; class-wide caution in personal/family history of
medullary thyroid carcinoma.
●
GnRH
agonists/antagonists (leuprolide, degarelix) — hormone-responsive prostate
cancer, endometriosis, precocious puberty; agonists cause an initial
testosterone flare, antagonists do not.
●
Somatostatin analogues
(octreotide) — acromegaly, carcinoid symptom control, variceal bleeding
adjunct.
●
GLP-2 analogue
(teduglutide) — short bowel syndrome; distinguish mechanism from GLP-1 on exam
distractor questions.
●
N-type calcium channel
blocker (ziconotide) — intrathecal use only for severe chronic pain; derived
from cone snail venom, a good "where do peptide drugs come from"
trivia point.
●
Natriuretic peptide
analogue (nesiritide) — acutely decompensated heart failure; limited by
hypotension risk and modest specificity.
References
Lowe,
D. "Peptides. Where to Begin?" In the Pipeline (Science Translational
Medicine blog), April 6, 2026.
Wang, L., Wang, N., Zhang, W., et al. "Therapeutic peptides: current applications and
future directions." Signal Transduction and Targeted Therapy 7, 48 (2022).
https://doi.org/10.1038/s41392-022-00904-4
Breen,
K., Yamaguchi, A. "FDA panel reviewing some peptides to consider loosening
regulations for unapproved therapies." CBS News, July 23, 2026.
NP Chronicles — Clinical education for NP students and new
graduates since 2012.
